CN113092752A

CN113092752A - Application of anti-SSA autoantibody as diagnosis marker of Hirschmannica

Info

Publication number: CN113092752A
Application number: CN202110336372.1A
Authority: CN
Inventors: 张彦; 郑懿; 朱云; 何秋明
Original assignee: Guangzhou Women and Childrens Medical Center
Current assignee: Guangzhou Women and Childrens Medical Center
Priority date: 2021-03-29
Filing date: 2021-03-29
Publication date: 2021-07-09
Anticipated expiration: 2041-03-29
Also published as: CN113092752B

Abstract

The invention relates to the technical field of biomedicine, in particular to application of an anti-SSA autoantibody as a diagnosis marker of Hirschsprung's disease. The invention finds that the anti-SSA autoantibody has the advantages of simple operation, no intervention, high flux and low cost in the congenital disease diagnosis of children, and fills the blank of the congenital megacolon plasma diagnosis. The diagnostic sensitivity and specificity of the method are good, and the AUC is 0.7756; the optimal limit corresponds to a sensitivity of 62.50% and a specificity of 74.36%, overcoming the disadvantages of the prior art without plasma diagnosis.

Description

Application of anti-SSA autoantibody as diagnosis marker of Hirschmannica

Technical Field

The invention relates to the technical field of biomedicine, in particular to application of an anti-SSA autoantibody as a diagnosis marker of Hirschsprung's disease.

Background

Hirschsprung disease (HSCR) is a birth defect disease of infantile enteric nerve dysplasia, and the pathological mechanism is that cells at the intestinal neural crest migrate and differentiate into enteric neurons to generate obstacle, so that the enteric nerve is deficient to generate persistent spasm, which is one of the common congenital intestinal tract diseases of infants. Early congenital megacolon is manifested as vomiting, abdominal distension, diarrhea and the like, which can lead to death of newborn infants or complications such as repeated enteritis after operation, intractable constipation and the like clinically, and seriously affect the growth, development and life quality of children patients.

The timely diagnosis and treatment of the congenital megacolon can reduce the risk of the congenital megacolon enteritis and obtain good prognosis. The diagnosis of the disease requires pathological sections of the diseased tissue after surgery. The preoperative diagnosis method mainly comprises barium enema, rectal biopsy and rectal manometry to judge whether to implement 'giant colon radical operation'. At present, barium enema is the most important diagnostic method, and the principle is that no nerve segment stenosis and proximal dilatation exist in the intestinal tract of a child suffering from congenital megacolon, and the colon is diagnosed as megacolon by the dilation and the stenosis after barium enema. However, the method can only diagnose the children with typical intestinal tract shape change, the sensitivity needs to be improved, and the diagnosis accuracy is about 80%. Rectal biopsy is to directly take the tissues of the straight intestine and detect whether the ganglion cells are lost, so the accuracy is high, but the sampling part has influence on the result. The method is invasive and very expensive, and is generally not readily applicable to infants who have a barium enema which is not obvious or is not suitable, for example, when Necrotizing Enterocolitis (NEC) is a possibility, the barium enema may cause intestinal perforation, and the barium enema is not suitable for diagnosis, and rectal biopsy is considered. Rectal manometry is to determine the innervation abnormality of the intestinal nerves by detecting the lack of relaxation of the internal anal sphincter, is only an auxiliary diagnosis method, has more false positives and false negatives, and cannot be used for single detection.

In view of the above, the present invention is particularly proposed.

Disclosure of Invention

In order to overcome the defects of the prior art, the invention aims to provide an anti-SSA antibody of a diagnosis marker of the Hirschsprung's disease and application thereof, and provides a new accurate and sensitive detection way for the diagnosis of the Hirschsprung's disease.

In order to achieve the purpose, the invention is realized by adopting the following technical scheme.

The invention relates to an application of a quantitative detection agent of an anti-SSA autoantibody in preparation of a diagnostic reagent, a kit or a test strip for Hirschsprung's disease.

Alternatively, for use as described above, the anti-SSA autoantibody is an anti-SSA autoantibody.

Optionally, for use as described above, the quantitative detection agent is for performing any one of the following methods:

radioimmunoassay, indirect immunofluorescence, dot immunogold filtration, mass spectrometry, immunoblotting and enzyme-linked immunosorbent assay.

Optionally, for use as described above, the quantitative detection agent is an SSA protein.

Alternatively, for use as described above, the SSA protein is conjugated to a solid support.

Alternatively, the solid support is selected from the group consisting of test tubes, EP tubes, multiwell plates, microplate wells and microspheres, for use as described above.

Optionally, for use as described above, the quantitative detection agent further comprises an anti-human Ig antibody.

Alternatively, for use as described above, the anti-human Ig antibody is an anti-human IgG antibody.

Alternatively, the anti-human Ig antibody is conjugated with a signal agent for use as described above.

Optionally, in the above-mentioned application, the sample to be tested detected by the quantitative detection agent is at least one of a blood, plasma, serum, tissue, cell, tissue or cell lysate sample.

Compared with the prior art, the invention has the beneficial effects that:

the invention finds that the anti-SSA autoantibody has the advantages of simple operation, no intervention, high flux and low cost in the congenital disease diagnosis of children, and fills the blank of the congenital megacolon plasma diagnosis. The diagnostic sensitivity and specificity of the method are good, and the AUC is 0.7756; the optimal limit corresponds to a sensitivity of 62.50% and a specificity of 74.36%, overcoming the disadvantages of the prior art without plasma diagnosis.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.

FIG. 1 is a diagram of an example of the present invention of a human autoimmune antigen chip for screening diagnostic markers in the plasma of a child suffering from Hirschsprung's disease;

FIG. 2 is a graph showing enzyme-linked immunosorbent assay (ELISA) assay for the level of anti-SSA antibody in the infant with congenital megacolon and other control groups according to one embodiment of the present invention;

FIG. 3 is a graph of the diagnostic value of ROC curve analysis of anti-SSA antibodies in the pre-natal megacolon in one embodiment of the invention.

Detailed Description

Reference will now be made in detail to embodiments of the invention, one or more examples of which are described below. Each example is provided by way of explanation, not limitation, of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

The invention finds that the anti-SSA autoantibody can be used as a diagnostic marker of the Hirschsprung's disease, has the advantages of simple operation, no intervention, high flux and low cost in the diagnosis of the Hirschsprung's disease of children, and fills the blank of the plasma diagnosis of the Hirschsprung's disease. The diagnostic sensitivity and specificity of the method are good, and the AUC is 0.7756; the optimal limit corresponds to a sensitivity of 62.50% and a specificity of 74.36%, overcoming the disadvantages of the prior art without plasma diagnosis.

The term "marker" or "biochemical marker" as used herein refers to a molecule to be used as a target for analyzing a patient test sample.

In some embodiments, the anti-SSA autoantibody is an anti-SSA autoantibody.

In the determination method of the present invention, the method of analyzing the expression of the autoantibody against the SSA protein is not particularly limited. For example, the absolute amount or concentration of these autoantibodies in a blood sample is not limited to measurement, and a relative amount or concentration may be measured. More specifically, for example, the amount, concentration or activity of the autoantibody or the like in a blood sample can be measured. Such methods are well known in the art, and by way of example, in some embodiments, the quantitative detection agent is used to perform any of the following methods:

Examples of the above-mentioned detection method include a time-of-flight MASS spectrometry (TOF-MASS) such as matrix assisted laser desorption/ionization time-of-flight MASS spectrometry (MALDI-TOF-MASS) and surface enhanced laser desorption/ionization time-of-flight MASS spectrometry (SELDI-TOF-MASS). The concentration or amount of autoantibodies can be grasped from the TOF-MASS chart by the molecular weight peak, other fragment peaks, their intensities, and the like. In addition, as in the case of ELISA, autoantibodies that selectively bind to the protein chip can also be detected using a secondary antibody that has a labeling group and can bind to the respective antibodies.

Among these methods, immunoassay is preferable as a method for performing the expression analysis. The immunoassay method has high sensitivity and accuracy, and can detect a slight change in the concentration of autoantibodies in blood. When the expression of the autoantibody according to the present invention is analyzed by enzyme-linked immunosorbent assay (ELISA), the diagnostic kit for colons congenital megacolon according to the present invention can be suitably used.

In some embodiments, the quantitative detection agent is an SSA protein.

An autoantigen fragment comprising an epitope recognized by an autoantibody can be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, or 1000 amino acids in length. The fragment can also be between 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, or 250 and one amino acid less than the full length of the autoantigen. Typically, these epitopes are characterized in advance so that autoantibodies to a given autoantigen are known to recognize the epitope. Methods of epitope mapping are well known in the art. An "epitope" is a site on an antigen, such as an autoantigen disclosed herein, that is recognized by an autoantibody. Obviously, the quantitative detection agent may also be at least one peptide selected from the group consisting of a fragment peptide, a denatured product, and a modified product of the SSA protein. The denatured product of SSA protein refers to a denatured product obtained by physical treatment such as heating, freezing, or ultraviolet rays, or chemical treatment such as application of a surfactant or a denaturant, and capable of specifically binding to the autoantibody. For example, a denatured product obtained by SDS or DTT treatment is mentioned. The modified product refers to a modified product obtained by modifying 1 or more amino acids and capable of specifically binding to the autoantibody. For example, a modified product obtained by treating with glutaraldehyde may be mentioned. The above-mentioned peptide may have mutation, substitution, deletion and/or addition of 1 or several amino acid residues as long as it can specifically bind to the above-mentioned autoantibody.

In some embodiments, the SSA protein is conjugated to a solid support.

In some embodiments, the solid support is selected from the group consisting of a test tube, an EP tube, a multi-well plate, a microplate well, and a microsphere.

The term "solid support" means that the carrier material is predominantly non-liquid-resistant, thereby allowing accurate and traceable localization of nucleic acids on the carrier material. The solid support can be selected from polystyrene, plastic, cellulose, polyacrylamide, polyethylene polypropylene, cross-linked dextran, glass, silicone rubber, agarose gel, etc. The preferred solid support is an elisa plate. It may contain 16, 32, 48, 64, 96 or more holes.

In the present invention, the term "microsphere" may be a sphere, a nearly sphere, a cube, a polyhedron or an irregular shape. The diameter of the microspheres is preferably 10nm to 1mm, for example 100nm, 500nm, 1 μm, 10 μm, 100 μm, 500 μm; preferably 400nm to 10 μm.

The microspheres have specific binding properties for the substance of interest (target or analyte) to be assayed on their surface.

The microspheres are preferably magnetic beads, and the magnetic material is contained in the composition. The magnetic substance may be a metal (simple metal or alloy), a nonmetal, or a composite of a metal and a nonmetal. Metals such as iron, alnico, and the like; non-metals, e.g. ferrite non-metals (preferably Fe)₂O₃Or Fe₃O₄Magnetic nanoparticles); a composite of metal and non-metal such as neodymium iron boron rubber magnetic composite.

The surface of the microsphere is modified with one or more active functional groups, wherein the active functional groups comprise-OH, -COOH and-NH₂-CHO, and-SO₃H. In some embodiments, the coated antigen and antibody are conjugated or bound to the microsphere by physisorption or direct chemical conjugation (e.g., bridging by a bridge). In particular, suitable techniques for constructing the bridge include, for example, covalent attachment, adsorption, non-covalent interactions, or combinations thereof. In some embodiments, direct bridging may be achieved by glutaraldehyde fixation, N-hydroxysuccinimide (NHS) chemistry, or 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC) NHS chemistry. Suitable means for indirect bridging include, for example, bridging via a peptide, protein, antibody, linker, or a combination thereof. In some embodiments, the indirect bridging to the solid support is via streptavidin and biotin.

In some embodiments, the quantitative detection agent further comprises an anti-human Ig antibody.

In some embodiments, the anti-human Ig antibody is an anti-human IgG antibody.

Anti-human Ig antibodies are antibodies directed against human Ig proteins, and anti-human IgG antibodies are antibodies directed against human IgG proteins.

In some embodiments, the anti-human Ig antibody is conjugated to a signal agent.

In other embodiments, the anti-human Ig antibody is not labeled with a signal substance, and the quantitative detection agent further comprises a second antibody against the anti-human Ig antibody labeled with a signal substance. After proteins and the like that have nonspecifically bound to peptides (SSA proteins) and the like are washed and removed with a buffer solution and the like, the secondary antibody is allowed to act. The secondary antibody binds to the autoantibody or the like bound to the peptide or the like. The secondary antibody is detected by a method corresponding to the signal substance.

In the present invention, the antibody used as a quantitative detection agent may be of IgA, IgD, IgG, IgE or IgM isotype or in the form of a single domain, such as a single domain antibody from a camelid. In some embodiments, the antibody used as a quantitative detection agent is an IgG antibody.

The buffer comprises, for example, one or more of the following components: phosphate buffer, NaCl, EDTA, Pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum or any combination, variant or equivalent thereof.

In the present invention, the signal substance is a substance capable of providing a signal to be detected, and in some embodiments, the signal substance is independently selected from any one or more of a chromophore, a digoxigenin-labeled probe, an electron-dense substance, colloidal gold, or an enzyme. The following non-limiting section lists these markers:

enzymes which produce a detectable signal, e.g.by colorimetry, fluorescence or luminescence, such as horseradish peroxidase, alkaline phosphatase, beta-galactosidase and glucose-6-phosphate dehydrogenase.

Chromophores such as fluorescence, quantum dots, fluorescent microspheres, luminescent compounds and dyes.

Groups with electron density that can be detected by electron microscopy or by its electrical properties, such as conductivity, amperometry, voltage measurement and resistance.

A detectable group, such as one whose molecular size is sufficient to induce a detectable modification in its physical and/or chemical properties; such detection can be achieved by optical methods (e.g., diffraction, surface plasmon resonance, surface variation and angle of contact variation) or physical methods (e.g., atomic spectroscopy and tunneling).

Electron-dense substances, e.g. radioactive molecules (e.g. of the type³²P，³⁵S or¹²⁵I)。

In some embodiments, the signal species is an Acridinium Ester (AE).

Further, acridine chemiluminescent substances include acridinium esters and acridinium sulfonamides.

Further, the acridine chemiluminescent substance includes acridine ester AE-NHS, acridine ester DMAE-NHS, acridine ester Me-DMAE-NHS, acridine ester NSP-DMAE-NHS, acridine salt NSP-SA-NHS, acridine hydrazide NSP-SA-ADH, etc.

Any biological sample containing autoantibodies may be used as the sample to be detected, including, but not limited to, serum, plasma, whole blood, saliva, urine, semen, sweat, tears, and body tissue. In some preferred embodiments, the sample to be tested by the quantitative detection agent is at least one of a blood, plasma, serum, tissue, cell, tissue or cell lysate sample.

As used herein, "tissue or cell lysate" may also be used in common with the terms "lysate", "lysed sample", "tissue or cell extract", and the like, to denote a sample and/or biological sample material comprising lysed tissue or cells, i.e. where the structural integrity of the tissue or cells has been disrupted. To release the contents of a cell or tissue sample, the material is typically treated with enzymes and/or chemical agents to lyse, degrade, or disrupt the cell walls and membranes of such tissues or cells. The skilled artisan is well familiar with suitable methods for obtaining a lysate. This process is encompassed by the term "lysis".

The diagnostic kit of the present invention preferably contains a normal control sample and a colons hirsutum control sample. When these samples are attached to the kit, the presence or absence of the congenital megacolon of the subject can be determined more objectively by performing the same experiment on these samples and comparing the measurement values with the results of the test sample.

The concentration or amount of autoantibodies contained in the sample is indirectly obtained by the intensity of color development or the like. The obtained measurement values can be converted into relative or absolute concentrations, amounts, activities, and the like by a calibration curve or the like.

The invention also relates to a method for diagnosing Hirschsprung's disease comprising quantitatively detecting anti-SSA autoantibodies in a sample to be examined, wherein an elevated level of anti-SSA autoantibodies is indicative of Hirschsprung's disease.

The term "indicative" when used in the context of autoantibodies for use with embodiments of the present invention includes autoantibodies whose presence or absence is determined by embodiments of the present invention which are typically present in a subject having a colons congenital. By "normally present" is meant that the autoantibody is often associated with the congenital megacolon. "frequently relevant" includes a probability of more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80% and particularly preferably more than 90% or 95%.

An ideal scenario for diagnosis is a situation where a single event or process may cause various diseases. In all other cases, correct diagnosis can be very difficult, especially when the etiology of the disease is not fully understood, as in the case of many cancer types. As the skilled artisan will appreciate, diagnosis without biochemical markers is 100% specific and with the same 100% sensitivity for a given multifactorial disease. Conversely, biochemical markers can be used to assess, for example, the presence or absence or severity of a disease with some likelihood or predictive value. Thus, in routine clinical diagnosis, a combination of various clinical symptoms and biological markers is often considered to diagnose, treat and control underlying diseases.

In the method of the present invention, the presence or absence of the onset of Hirschsprung's disease is then determined from the expression analysis results obtained. That is, the more severe the onset of the congenital megacolon or the symptoms thereof, the higher the concentration or amount of the autoantibody according to the present invention in blood. Thus, based on the results of expression analysis of the autoantibody according to the present invention, a positive antibody can be determined when the expression level is high, and a negative antibody can be determined when the expression level is low.

In fact, the boundary between positive and negative, i.e., cutoff value, can be varied according to the definition and severity of the Hirschsprung's disease, the method of analysis of the expression of the autoantibodies to which the present invention relates. Therefore, at a stage where there is no general standard, it is necessary for the practitioner of the method of the present invention to determine the expression analysis method and the cutoff value in advance by preliminary experiments or the like and then perform the measurement.

In some embodiments, the subject is a patient below 18, e.g., 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 year old. Or in infants, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 months of age.

Embodiments of the present invention will be described in detail below with reference to examples.

The samples adopted by the invention are all from Guangzhou city woman child medical center, and all the experimental tissues and blood samples are collected by ethical committee authorization and patient consent of Guangzhou city woman child medical center.

The test results of the invention are all analyzed by statistics, t test is used for evaluating the difference between two groups, p is less than 0.05 for representing statistical significance, and two-sided test is used for all p values. Statistical analysis was performed using R and graphpad8.0 software.

The congenital megacolon disease is one of common congenital intestinal diseases of children, namely, the congenital megacolon disease is clinically divided into a short segment type, a common type, a long segment type and a full colon type according to increasing severity because the colon is lack of ganglion cells to cause continuous spasm of an intestinal canal, excrement is stagnated in the proximal colon, and the proximal colon is thickened and expanded. Short-segment lesions are positioned at the near and middle segments of the rectum and are not more than 6.5cm away from the anal canal; the common lesions were located at the proximal rectum end or distal end of the rectosigmoid colon, about 9cm from the anal canal; long segment lesions extend to the sigmoid or descending colon; the colon-wide lesion reaches the whole colon and the tail end of the ileum within 30cm from the ileocecal valve.

The autoantibodies of the present invention are antibodies that erroneously target and damage a specific tissue or organ of the body.

The SSA of the invention is an RNase-resistant cytoplasmic ribonucleoprotein; the anti-SSA antibody is an autoantibody, preferably an IgG antibody, produced against SSA in the nucleus of a cell.

The "ROC curve" of the present invention is a curve of 1-specificity (false positive rate) and sensitivity (true positive rate) changes, reflecting the diagnostic capabilities of the classifiers. A good classifier has a ratio of true positive rate to false positive rate of greater than 1, away from the 45 degree line.

The "AUC" refers to the area under the ROC curve, is between 0.1 and 1, and is used for evaluating the quality of the classifier, and the closer to 1, the better the classifier is.

The invention screens the blood plasma of the infant with the congenital megacolon by the human self-immune antigen chip, and obtains the anti-SSA antibody with high expression of the blood plasma of the infant with the congenital megacolon by taking the blood plasma of other intestinal diseases and the blood plasma of the infant with a healthy group as a contrast. And the further effect is verified by an enzyme-linked immunosorbent assay (ELISA) method in an independent sample.

Example 1 plasma and tissue sample Collection and grouping

Plasma samples were divided into the hirschsprung child group (37 cases), the other enteropathy control group (18 cases), the healthy child group (30 cases), the age ranged from 3 months to 3 years, the gender male 3/4 was male, and the age and gender of the disease and control groups were matched. All samples were from the Guangzhou city women's Children medical center, and the healthy children group had blood samples left after physical examination. The blood sampling mode is anticoagulation blood sampling, centrifugal separation of blood plasma and freezing storage of samples. The colon tissue sample was a group of children patients with hirschsprung's disease (36 cases), which was a diseased tissue surgically removed. Other intestinal disease controls (total of 11 colon tissues including anal stenosis and intestinal stenosis fistulation).

Example 2 screening of human autoimmune antigen chips and analysis of differentially expressed autoantibodies

Plasma of 5 children patients with Hirschsprung (HSCR) and 5 of the plasma of children in the healthy group (HC) and other intestinal Diseases (DC) groups were screened using an autoimmune antigen chip provided by cantonese biotechnology limited, guangzhou, which contains lgG detection of over 100 autoimmune antibodies, raw data, after subtraction of negative controls, were normalized by RLM method to obtain results for inter-group difference analysis using M statistics, and fig. 1 shows a cluster analysis graph of the different autoantibodies, from which it can be seen that the ribonucleoprotein antigen SSA was significantly higher in plasma of children with congenital dyscrasia than in the control group (p 0.046).

Example 3 enzyme-linked immunosorbent assay (ELISA) detection of anti-SSA antibodies

To verify the diagnostic effect of anti-SSA antibody on the congenital megacolon, we collected plasma from megacolon patients (37 cases), other intestinal disease controls (including 18 plasma samples of anal stenosis and intestinal stenosis fistulizing children), and healthy child controls (30 cases), and detected the level of anti-SSA antibody in plasma by enzyme-linked immunosorbent assay (ELISA), which is human anti-SSA antibody (SSA-Ab) enzyme-linked immunosorbent assay (ELISA) kit (shanghai fine science and technology ltd). The results are shown in FIG. 2, which shows that anti-SSA antibodies in the plasma of megacolon patients are significantly higher than the healthy children control group (p <0.01), not different from the bowel disease control group, and higher than the control group in which bowel disease and healthy children are combined (p < 0.01).

Example 4 ROC Curve analysis

FIG. 3 shows the ROC curve used to evaluate the diagnostic effect of anti-SSA antibodies on Hirschsprung's disease. AUC of 0.7756; the optimal limit corresponds to a sensitivity of 62.50% and a specificity of 74.36%. It follows that anti-SSA antibodies can effectively diagnose the congenital megacolon.

In conclusion, the invention obtains the anti-SSA antibody with high plasma expression of the infant with the congenital megacolon through the screening of the human autoimmune antigen chip. And the enzyme-linked immunosorbent assay (ELISA) method is used in an independent sample to verify that the anti-SSA antibody in the megacolon group (HSCR) is obviously higher than that of other disease and healthy control groups, and can effectively diagnose the infant with congenital megacolon, and the AUC is 0.7756; the optimal limit corresponds to a sensitivity of 62.50% and a specificity of 74.36%. The anti-SSA antibody can be used as a plasma diagnostic marker of the Hirschsprung's disease, is used for diagnosing the disease and fills the blank of blood diagnosis of the Hirschsprung's disease.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. The application of the quantitative detection agent of the anti-SSA autoantibody in the preparation of a diagnostic reagent, a kit or a test strip for Hirschsprung's disease.

2. The use of claim 1, wherein the anti-SSA autoantibody is an anti-SSA autoantibody to IgG.

3. The use of claim 1, wherein the quantitative detection agent is used to perform any one of the following methods:

4. The use of claim 1, wherein the quantitative detection agent is an SSA protein.

5. The use of claim 4, wherein the SSA protein is conjugated to a solid support.

6. The use of claim 5, wherein the solid support is selected from the group consisting of test tubes, EP tubes, multiwell plates, microplate wells, and microspheres.

7. The use of any one of claims 4 to 6, wherein the quantitative detection agent further comprises an anti-human Ig antibody.

8. The use of claim 7, wherein said anti-human Ig antibody is an anti-human IgG antibody.

9. The use according to claim 7, wherein said anti-human Ig antibody is conjugated with a signal substance.

10. The use according to any one of claims 1 to 6, 8 and 9, wherein the sample to be tested to be detected by the quantitative detection agent is at least one of a blood sample, a plasma sample, a serum sample, a tissue sample, a cell sample, a tissue sample or a cell lysate sample.